HIV-1 entry inhibitors: new targets, novel therapies (Q35044760)

6 August 2017

1 reference

title

HIV-1 entry inhibitors: new targets, novel therapies (English)

1 reference

6 August 2017

1

Theodore C Pierson

1 reference

6 August 2017

2

Robert W Doms

1 reference

6 August 2017

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

85

1 reference

6 August 2017

2

1 reference

6 August 2017

113-118

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

6 August 2017

1 reference

7 January 2021

HIV-1 drug resistance in newly infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Reduced antiretroviral drug susceptibility among patients with primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Transmission of antiretroviral-drug-resistant HIV-1 variants

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Potential new therapies for the treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

DC-SIGN and DC-SIGNR: helping hands for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

HIV gp120 receptors on human dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Rhesus macaque dendritic cells efficiently transmit primate lentiviruses independently of DC-SIGN

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

A new classification for HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Structural basis for membrane fusion by enveloped viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

A general model for the transmembrane proteins of HIV and other retroviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Core structure of gp41 from the HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Atomic structure of the ectodomain from HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Energetics of the HIV gp120-CD4 binding reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Structural basis for paramyxovirus-mediated membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Structure of influenza haemagglutinin at the pH of membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Dissection of a retrovirus envelope protein reveals structural similarity to influenza hemagglutinin.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

A soluble form of CD4 (T4) protein inhibits AIDS virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

HIV infection is blocked in vitro by recombinant soluble CD4.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

A soluble CD4 protein selectively inhibits HIV replication and syncytium formation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Soluble CD4 molecules neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Expression and Characterization of CD4-IgG2, a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Safe use of the CXCR4 inhibitor ALX40-4C in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

HIV fusion and its inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Capture of an early fusion-active conformation of HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2802%2900235-3

7 January 2021

10.1016/S0165-2478(02)00235-3

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12527216